Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Communications"
DOI: 10.1002/cac2.12385
Abstract: Treatment options for Chinese patients with locally advanced or metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line chemotherapy are limited. This study (ORIENT‐3) aimed to evaluate the efficacy and safety of sintilimab versus… read more here.
Keywords: cell; metastatic squamous; line; treatment ... See more keywords
Cost‐effectiveness of first‐line versus second‐line use of domestic anti‐PD‐1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5440
Abstract: Programmed cell death protein‐1/programmed cell death ligand‐1 (PD‐1/L1) inhibitor is a promising therapeutic option that can be used as either a first‐line or second‐line treatment for driver‐negative advanced or metastatic squamous non‐small cell lung cancers… read more here.
Keywords: cell; metastatic squamous; first line; line ... See more keywords
Treatment outcomes of advanced/metastatic extramammary Paget's disease in Korean patients: KCSG-RC20-06.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.6190
Abstract: BACKGROUND Extramammary Paget's disease (EMPD) is rare. There are no standard treatments due to its rarity and few clinical trials. METHODS The objective of this multicenter study was to investigate treatment outcomes of Korean patients… read more here.
Keywords: taxane; treatment; advanced metastatic; chemotherapy ... See more keywords
Nine‐year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31285
Abstract: To the authors' knowledge, the survival benefit of local therapy in the setting of advanced prostate cancer remains unknown. The authors investigated whether prostate‐directed treatment with either surgery or radiotherapy versus conservative treatment in the… read more here.
Keywords: prostate; advanced metastatic; therapy; prostate cancer ... See more keywords
Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
Sign Up to like & getrecommendations! Published in 2022 at "Hepatology"
DOI: 10.1002/hep.32804
Abstract: Background and Aims: This study aimed to investigate safety and efficacy of silmitasertib, an oral small molecule casein kinase 2 inhibitor, plus gemcitabine and cisplatin (G+C) versus G+C in locally advanced/metastatic cholangiocarcinoma. Approach and Results:… read more here.
Keywords: locally advanced; metastatic cholangiocarcinoma; advanced metastatic; study ... See more keywords
Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD‐L1‐positive locally advanced or metastatic non–small‐cell lung cancer: KEYNOTE‐042 China Study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Cancer"
DOI: 10.1002/ijc.33399
Abstract: In the global KEYNOTE‐042 study (Clinicaltrials.gov, NCT02220894), pembrolizumab significantly improved overall survival (OS) vs chemotherapy in patients with previously untreated programmed death ligand 1 (PD‐L1)‐positive locally advanced/metastatic non–small‐cell lung cancer (NSCLC) without EGFR/ALK alterations. We… read more here.
Keywords: chemotherapy; advanced metastatic; study; keynote 042 ... See more keywords
Characteristics and response to next‐generation sequencing‐guided therapy in locally advanced or metastatic esophageal cancer
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34315
Abstract: Esophageal cancer (EC) is a main cause of cancer‐related deaths. However, genomic alterations and the clinical value of next‐generation sequencing (NGS) in advanced or metastatic EC for precision therapy remain largely unclear. Herein, we performed… read more here.
Keywords: esophageal cancer; therapy; next generation; advanced metastatic ... See more keywords
Do locally advanced and metastatic human epithelial cancers evolve in ‘placental/decidual-like microenvironments’?
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-018-1982-5
Abstract: Successful tumor microenvironments eventually kill the host. They are not only meant to nourish and protect tumor development, but to give them the right “soil” for perpetual malignant properties such as tissue invasion and metastasis.… read more here.
Keywords: advanced metastatic; epithelial cancers; human epithelial; cancers evolve ... See more keywords
Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01394-y
Abstract: Introduction Currently available second-line (2L) therapies for advanced/metastatic esophageal squamous cell carcinoma (adv/met ESCC) include the taxanes paclitaxel and docetaxel. In clinical trials, such therapies have provided only modest improvements in survival. Few studies have… read more here.
Keywords: advanced metastatic; metastatic esophageal; patients receiving; adv met ... See more keywords
Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models
Sign Up to like & getrecommendations! Published in 2018 at "Applied Health Economics and Health Policy"
DOI: 10.1007/s40258-018-0452-0
Abstract: ObjectivesTo assess the cost-effectiveness of nivolumab for patients with advanced or metastatic squamous non-small-cell lung cancer (NSCLC) progressed on or after platinum-based chemotherapy using a modelled economic evaluation.MethodsBoth partition survival (PS) and Markov models, comprised… read more here.
Keywords: advanced metastatic; treatment; markov models; health ... See more keywords
Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Pharmacoeconomics"
DOI: 10.1007/s40273-018-0752-0
Abstract: ObjectivesPembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1)–positive tumors in the first-line… read more here.
Keywords: advanced metastatic; non small; metastatic non; analysis ... See more keywords